DLDonna M. Leippe

Donna M. Leippe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Donna M. Leippe has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Jolanta Vidugiriene

    Research and Development, Promega Corporation, Madison, Wisconsin 53711, United States

    3 shared publications
  • David T. Beattie

    Maze Therapeutics, South San Francisco, California 94080, United States

    2 shared publications
  • Hanne Merritt

    Maze Therapeutics, South San Francisco, California 94080, United States

    2 shared publications
  • Kevin T. Mellem

    Maze Therapeutics, South San Francisco, California 94080, United States

    2 shared publications
  • Rebeca Choy

    Maze Therapeutics, South San Francisco, California 94080, United States

    2 shared publications
  • Dieter H. Klaubert

    Promega Biosciences, Inc., San Luis Obispo, CA, USA

    1 shared publication

Latest Publications

  • Open Access

    Bioluminescent Assay for the Quantification of Cellular Glycogen Levels

    by Donna Leippe, Rebeca Choy, Gediminas Vidugiris, Hanne Merritt, Kevin T. Mellem, David T. Beattie, Julie C. Ullman, Jolanta Vidugiriene

    Glycogen is a large polymer of glucose that functions as an important means of storing energy and maintaining glucose homeostasis. Glycogen synthesis and degradation pathways are highly regulated and their dysregulation can contribute to disease. Glycogen storage diseases are a set of disorders that arise from improper glycogen metabolism. Glycogen storage disease II, known as Pompe disease, is caused by a genetic mutation that leads to increased glycogen storage in cells and tissues, resulting in progressive muscle atrophy and respiratory decline for patients. One approach for treating Pompe disease is to reduce glycogen levels by interfering with the glycogen synthesis pathway through glycogen synthase inhibitors. To facilitate the study of glycogen synthase inhibitors in biological samples, such as cultured cells, a high-throughput approach for measuring cellular glycogen was developed. A bioluminescent glycogen detection assay was automated and used to measure the glycogen content in cells grown in 384-well plates. The assay successfully quantified reduced glycogen stores in cells treated with a series of glycogen synthase 1 inhibitors, validating the utility of the assay for drug screening efforts and demonstrating its value for therapy development and glycogen metabolism research.


  • Open Access

    A Bioluminescent Assay for Quantification of Cellular Glycogen Levels

    by Donna Leippe, Rebeca Choy, Gediminis Vidugiris, Hanne Merritt, Kevin T. Mellem, David T. Beattie, Julie C. Ullman, Jolanta Vidugiriene

    Glycogen is a large polymer of glucose that functions as an important means of storing energy and maintaining glucose homeostasis. Glycogen synthesis and degradation pathways are highly regulated and their dysregulation can contribute to disease. Glycogen storage diseases are a set of disorders that arise from improper glycogen metabolism. Glycogen storage disease II, known as Pompe disease, is caused by a genetic mutation that leads to increased glycogen storage in cells and tissues, resulting in progressive muscle atrophy and respiratory decline for patients. One approach for treating Pompe disease is to reduce glycogen levels by interfering with the glycogen synthesis pathway through glycogen synthase inhibitors. To facilitate the study of glycogen synthase inhibitors in biological samples, such as cultured cells, a high-throughput approach for measuring cellular glycogen was developed. A bioluminescent glycogen detection assay was automated and used to measure glycogen content in cells grown in 384-well plates. The assay successfully quantified reduced glycogen stores in cells treated with a series of glycogen synthase 1 inhibitors, verifying inhibitor activity in biological systems and validating the utility of the assay for glycogen metabolism studies.

  • Open Access

    A Bioluminescent Assay for the Sensitive Detection of Proteases

    by Donna M. Leippe, Duy Nguyen, Min Zhou, Troy Good, Thomas A. Kirkland, Mike Scurria, Laurent Bernad, Tim Ugo, Jolanta Vidugiriene, James J. Cali, et al.

    A bioluminescent general protease assay was developed using a combination of five luminogenic peptide substrates. The peptide-conjugated luciferin substrates were combined with luciferase to form a homogeneous, coupled-enzyme assay. This single-reagent format minimized backgrounds, gave stable signals, and reached peak sensitivity within 30 min. The bioluminescent assay was used to detect multiple proteases representing serine, cysteine, and metalloproteinase classes. The range of proteases detected was broader and the sensitivity greater, when compared with a standard fluorescent assay based on cleavage of the whole protein substrate casein. Fifteen of twenty proteases tested had signal-to-background ratios >10 with the bioluminescent method, compared with only seven proteases with the fluorescent approach. The bioluminescent assay also achieved lower detection limits (≤100 pg) than fluorescent methods. During protein purification processes, especially for therapeutic proteins, even trace levels of conta... Luminous Assays of Numerous Proteases Proteases are an unavoidable contaminant during protein purification and, if present at high enough levels, can significantly impact the yield, stability, and activity of purified proteins. Sensitive protease assays are required to monitor the reduction of contaminating protease activity during protein purification and to verify that the final purified protein is protease-free. While synthetic peptide substrates can be used to assay for a specific protease, this approach is not suitable when the goal is to assay multiple or unknown proteases. In such cases, whole proteins such as casein or gelatin have been used as universal substrates in fluorogenic or chromogenic assays. But these assays suffer from the need for multiple steps, long incubation times, and poor sensitivity. To overcome these drawbacks, D. Leippe and colleagues describe a new sensitive bioluminescent assay for general protease activity in the current issue. Bioluminescent assays that are more sensitive...


  • Open Access

    Cell-Free Expression of Protein Kinase a for Rapid Activity Assays

    by Donna M. Leippe, Kate Qin Zhao, Kevin Hsiao, Michael R. Slater

    Functional protein analysis often calls for lengthy, laborious in vivo protein expression and purification, and can be complicated by the lack of stability of the purified protein. In this study, we demonstrate the feasibility of a simplified procedure for functional protein analysis on magnetic particles using cell-free protein synthesis of the catalytic subunit of human cAMP-dependent protein kinase as a HaloTag® fusion protein. The cell-free protein synthesis systems provide quick access to the protein of interest, while the HaloTag technology provides efficient, covalent protein immobilization of the fusion protein, eliminating the need for further protein purification and minimizing storage-related stability issues. The immobilized cPKA fusion protein is assayed directly on magnetic beads and can be used in inhibitor analyses. The combination of rapid protein synthesis and capture technologies can greatly facilitate the process of protein expression and activity screening, and therefore, can become a valuable tool for functional proteomics studies.